内科

目的探究泮托拉唑钠联合奥曲肽治疗肝硬化上消化道出血患者的临床效果及对患者炎症指标水平的影响。方法选取2018年10月至2020年1月我院收治的肝硬化上消化道出血患者135例为研究对象，根据治疗方案不同分为对照组（66例）和观察组（69例）。两组患者均进行常规禁食、禁水、补充血容量、维持电解质平衡等治疗以及抗病毒治疗。在此基础上，对照组患者加用泮托拉唑钠治疗，观察组患者加用泮托拉唑钠+醋酸奥曲肽注射液治疗，疗程3天。比较两组患者的临床疗效、治疗前后的血清炎症指标水平及不良反应发生情况。结果观察组患者的治疗总有效率（95.7%）显著高于对照组（83.3%），差异有统计学意义（P＜0.05）。治疗前，两组患者的IL-1β、TNF-α、PCT水平比较，差异无统计学意义（P＞0.05）；治疗3 d后，两组患者的IL-1β、TNF-α、PCT水平均显著降低，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。观察组患者的不良反应发生率（10.6%）略低于对照组（11.6%），但差异无统计学意义（P＜0.05）。结论泮托拉唑钠联合奥曲肽治疗肝硬化上消化道出血患者临床疗效显著，能显著缓解机体炎症反应，但不会增加不良反应的发生。

ObjectiveTo explore the clinical effect of pantoprazole sodium combined with octreotide in the treatment of patients with liver cirrhosis upper gastrointestinal bleeding, and its influence on inflammatory indexes levels of patients. MethodsA total of 135 patients with liver cirrhosis upper gastrointestinal bleeding admitted to our hospital from October 2018 to January 2020 were selected as the research objects. According to the different treatment options, they were divided into control group (66 cases) and observation group (69 cases). Both groups of patients were given conventional treatments, including fasting, water-depriving, blood volume supplementation, electrolyte balance maintenance, and antiviral treatment, based on which patients in the control group were additionally treated with pantoprazole sodium, whereas patients in the observation group were additionally treated with pantoprazole sodium + octreotide acetate injection, for a three-day treatment course. The clinical efficacy, serum inflammatory indexes levels before and after treatment, and the occurrence of adverse reactions were compared between the two groups. ResultsThe total effective rate of treatment in the observation group (95.7%) was significantly higher than that in the control group (83.3%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences in the levels of IL-1β, TNF-α, and PCT between the two groups before treatment(P＞0.05). After 3 days of treatment, the levels of IL-1β, TNF-α, and PCT of the two groups significantly decreased, and the levels mentioned above in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P＜0.05). The incidence of adverse reactions in the observation group (10.6%) was slightly lower than that in the control group (11.6%), but the difference was not statistically significant. ConclusionPantoprazole sodium combined with octreotide has a significant clinical effect in the treatment of patients with liver cirrhosis upper gastrointestinal bleeding, which can significantly alleviate the inflammatory response of the body, but it will not increase the occurrence of adverse reactions.